Figure 2.

Proportions of febrile patients following treatment. CQ, Chloroquine, AQ, Amodiaquine; SP, Sulfadoxine-Pyrimethamine; AS, artesunate; On day 1, Significant difference to SP group (P < 0.05), SP vs. AQ+SP, SP vs. AQ+AS; At day 2, Significant difference to SP group (P < 0.05), SP vs. AQ+AS; On day 14, Significant difference to CQ group (P < 0.05), CQ vs. AQ, CQ vs. SP, CQ vs. AQ+SP, CQ vs. AQ+AS